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Challenges in lung cancer therapy during the COVID-19 
pandemic
Coronavirus disease 2019 (COVID-19), caused by 
the newly identified strain of the coronavirus family 
severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2), has rapidly evolved into a worldwide 
pandemic and caused a public health emergency of 
major international concern.1,2 As a result, a profound 
reorganisation of hospital wards and clinical activities 
is happening worldwide to deal with the increasing 
number of COVID-19-positive patients who require 
hospitalisation and intensive care support.3 This 
comprehensive reallocation of health resources is 
of particular concern in patients such as those with 
underlying chronic diseases, including cancer.
The prioritisation of health support towards patients 
with COVID-19 is raising apprehension within the 
medical oncology community, in which physicians 
are increasingly being forced to select which patients 
should receive anticancer therapy on the basis of 
who is most likely to have a positive outcome.4 In 
this context, the threat of COVID-19 infection might 
also factor into decision making—a role which could 
possibly be lessened by knowledge of the COVID-19 
status of patients suitable for anticancer therapy.4 This 
already dismal scenario seems to be even more severe 
for patients with lung cancer because of the high risk of 
interference of COVID-19 with their effective diagnostic 
and therapeutic management by treating physicians.
Clinical manifestations of COVID-19 range from 
asymptomatic, to mild symptoms (such as cold, fever, 
cough, or other non-specific signs), to severe pneumonia 
leading to acute respiratory distress syndrome, which 
occurs in 17–29% of infected individuals.2 Mortality 
due to COVID-19 has been reported in about 3% of 
COVID-19-positive patients in the Chinese population,5 
while higher mortality rates are being reported in Italy,6 
which is, after the USA, currently the country with the 
second highest number of confirmed COVID-19 cases 
worldwide.7
In the early phase of COVID-19-induced pneumonia, 
the main CT findings include multifocal peripheral and 
basal ground-glass opacities, crazy paving patterns, 
traction bronchiectasis, and air bronchogram signs. 
A progressive transition to consolidation, together 
with pleural effusion, extensive small lung nodules, 
irregular interlobular or septal thickening, and 
adenopathies, characterise the more advanced phase 
of the disease.8,9 These radiological manifestations 
can overlap with CT findings that are often found in 
patients with lung cancer upon disease progression 
or onset of concomitant pneumonia due to over-
lapping opportunistic infections. Regarding clinical 
manifestations, the worsening of pulmonary symptoms 
during lung cancer progression can be similar to that 
typical of COVID-19, adding further complexity to 
the thorough assessment of the course of disease in 
lung cancer patients. Together, these similarities can 
pose a major challenge to clinicians in distinguishing 
lung cancer evolution from a potential COVID-19 
super-infection on the basis of radiological and clinical 
evidence, and, importantly, these specific conditions 
require very different therapeutic approaches.
Adding further complexity to this scenario, 
pneumonitis can also be induced by immune checkpoint 
inhibitor therapy, an effective and widely used standard-
of-care treatment for lung cancer in various treatment 
lines and settings.10 Immune checkpoint inhibitor-
related pneumonitis has been reported in about 2% of 
cancer patients,11 with a seemingly higher incidence 
in patients with lung cancer.12 Similar to COVID-19 
infection, the clinical symptoms of immune checkpoint 
inhibitor-induced pneumonitis are often not specific, 
consisting mainly of cough (or its worsening), chest 
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Figure: CT scans of pneumonia due to COVID-19 and immune checkpoint 
inhibitor therapy
(A) Axial lung image (without intravenous contrast) of 49-year-old man with 
COVID-19, showing two sub-solid areas in the upper right lobe (arrows). 
(B) Axial lung image (without intravenous contrast) of an immune checkpoint 
inhibitor-treated 76-year-old man with metastatic melanoma, showing a 
sub-solid area and ground-glass opacities with a rounded morphology in the 
upper right lobe (arrows). COVID-19=coronavirus disease 2019.
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pain, dyspnoea, and fever. Additionally, CT assessment 
of immune checkpoint inhibitor-related pneumonitis 
shows radiological findings similar to those typical 
of COVID-19-induced pneumonia (figure), thus 
hindering discrimination between the two clinical 
entities. Similarly, tyrosine kinase inhibitors can induce 
radiological patterns of interstitial-like pneumonitis, 
which develops in 4% of patients with epidermal 
growth factor receptor-mutant lung cancer treated with 
osimertinib.13
In this scenario, standard chemotherapy does not 
seem to represent a suitable or potentially safer 
alternative to immune checkpoint inhibitor therapy —
neither for treating physicians who want to avoid the 
overlapping immune checkpoint inhibitor-related and 
COVID-19-related radiological and clinical changes, 
or for patients who are unsuitable for immune 
checkpoint inhibitor therapy. First, combinations of 
chemotherapies and immunotherapies have shown 
the best efficacy and represent the standard of care in a 
large group of patients without oncogene-driven lung 
cancer and without high PD-L1 expression in tumour 
cells. Second, the development of chemotherapy-
associated pneumonitis is known to occur in up to 16% 
of treated patients,14 and cytotoxic chemotherapy has 
immunosuppressive activity.15 Notably, administration 
of chemotherapy within the month preceding COVID-19 
diagnosis has been shown to be associated with a higher 
risk of severe infection-related complications.16
The clinical and biological aggressiveness of lung 
malignancies clearly does not allow for anticancer 
therapy to be withheld or postponed. Thus, while 
awaiting specific evidence-based guidelines, the 
comprehensive management of patients with lung 
cancer during the COVID-19 pandemic should involve 
specific and careful attention to their clinical and 
radiological pulmonary signs, more so than for patients 
with other types of tumour. From a practical viewpoint, 
it seems reasonable to suggest that patients with lung 
cancer undergo systematic testing for SARS-CoV-2 at 
the beginning of treatment and whenever it is deemed 
necessary by the treating physician in the course of 
therapy. This strategy might become more feasible 
with the increasing availability and progressive use 
of real-time PCR assays that can provide COVID-19 
status results within an hour.17 Furthermore, the 
availability of laboratory IgM or IgG testing to evaluate 
the exposure and immunity to SARS-CoV-2 infection 
will be helpful when the COVID-19 pandemic begins to 
decline. Allocating resources for these methodological 
approaches to patients with lung cancer should 
facilitate the most appropriate clinical management by 
multidisciplinary lung cancer care teams.
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The coronavirus disease 2019 (COVID-19) pandemic, 
caused by severe acute respiratory syndrome 
corona virus 2 (SARS-CoV-2), continues to spread globally 
despite unprecedented social isolation and restrictions 
resulting in widespread economic decline. More than 
3·2 million people have been infected and more than 
230 000 of them have died. To date, no treatments 
have been definitively shown to be effective; however, 
a multipronged approach to mitigate transmission, 
morbidity, and mortality is ongoing.1 While upstream 
prevention strategies such as vaccination are ideal, these 
strategies are unlikely to be available in time to address 
current clinical need. Instead, fast-tracking of drug 
development and repurposing of approved drugs2 has 
facilitated and expedited clinical trials that might hasten 
effective therapeutics. Many of these drugs act, at least 
in part, to directly limit viral replication. By contrast, the 
use of interleukin-6 (IL-6) inhibition might have benefits 
by controlling the pathological immune response to the 
virus. Here, we expand on the theoretical basis of IL-6 
inhibition and propose potential benefits from other 
immunomodulators that could, in theory, prove more 
efficacious.
For the latter phase of convalescence, hospitalised 
patients with COVID-19 can develop a syndrome of 
dysregulated and systemic immune overactivation 
described as a cytokine storm or hyperinflammatory 
syndrome that worsens acute respiratory distress 
syndrome and can lead to multisystem organ 
failure.3–5 The scarce systematic data available have 
shown an association between ferritin, lactate 
dehydrogenase, IL-6, IL-1, d-dimer, and C-reactive 
protein and severe disease.6–8 If this group can be 
identified before decompensation, early and aggressive 
immunomodulatory treatment might prevent need for 
intubation and extracorporeal membrane oxygenation. 
To date, observational studies9 suggest a possible benefit 
but results of placebo-controlled randomised clinical 
trials are not yet available. Given the methodological 
limitations of existing studies, more evidence is needed. 
With the rapidly expanding number of critically ill 
patients, there is an urgent need to identify multiple 
putative biological targets. While IL-6 inhibition 
attenuates key aspects of the cytokine cascade, we posit 
other immune targets of inhibition to be considered and 
their potential to be more efficacious in the setting of 
COVID-19, specifically IL-1 inhibitors and Janus kinase 
(JAK) inhibitors.
Observational data show overlapping clinical features 
in severe COVID-19 with macrophage activating 
syndrome (MAS) and secondary haemophagocytic 
lymphohistiocytosis (HLH).7 Hyperinflammatory states, 
specifically in fatal cases, highlight why consideration of 
HLH and MAS therapies are warranted. Furthermore, the 
pathogenesis underlying SARS-CoV-2 involves several 
key pathways that can be manipulated, and use of these 
therapies can mitigate the propagation of an overdriven 
inflammatory response (figure).10 Although few patients 
with severe COVID-19 would meet criteria for MAS, 
it is proposed that they are on the spectrum and that 
MAS or secondary HLH therapies might be of benefit. 
IL-1 inhibitors are key therapeutics in the treatment of 
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